Keratoacanthoma-appearing melanoma metastases in a patient receiving pembrolizumab therapy
| Autor: | Nicholas M. Bontumasi, Mohammed M. Milhem, Karolyn A. Wanat, Heather K. Schopper |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty Keratoacanthoma medicine.drug_class Case Report 02 engineering and technology Dermatology Pembrolizumab Monoclonal antibody Metastasis 03 medical and health sciences 020210 optoelectronics & photonics 0302 clinical medicine Internal medicine 0202 electrical engineering electronic engineering information engineering medicine melanoma metastasis In patient business.industry Melanoma medicine.disease 030220 oncology & carcinogenesis Cutaneous melanoma pembrolizumab business keratoacanthoma |
| Zdroj: | JAAD Case Reports |
| ISSN: | 2352-5126 |
| Popis: | Pembrolizumab is a new monoclonal antibody chemotherapeutic agent that binds to the programmed cell death–1 receptor and decreases the down-regulation of lymphocytes in patients treated for metastatic melanoma.1 Because this drug is relatively new, little is known about its effect on cutaneous melanoma metastases. We report a case detailing the unexpected keratoacanthomalike appearance of melanoma metastases in a patient receiving pembrolizumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|